García-Morteo O, Maldonado-Cocco J A, Cuttica R, Garay S M
Eur J Rheumatol Inflamm. 1987;8(1):49-53.
There is little consistency in drug treatment of children with juvenile rheumatoid arthritis, in part because there are few controlled studies of the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in this disease. To determine the safety and efficacy of piroxicam in children with juvenile rheumatoid arthritis, 26 patients ranging in age from three to 25 years were randomly assigned to treatment with piroxicam or naproxen. The number of painful and swollen joints decreased significantly (p less than 0.05) in the piroxicam group. The overall assessment of the investigators was that 67% of the patients in the piroxicam group showed clinical improvement, in contrast to 38% of the naproxen-treated patients. Side effects in the piroxicam group were mild and transient, and no patient was removed from the study because of side effects. The recurrence of a cutaneous rash necessitated the removal of one naproxen-treated patient from the study. Although the results should be interpreted with caution because of the small sample size, piroxicam appears to be more effective and better tolerated than naproxen in this study.
青少年类风湿性关节炎患儿的药物治疗缺乏一致性，部分原因是针对该疾病使用非甾体抗炎药（NSAIDs）的对照研究较少。为了确定吡罗昔康对青少年类风湿性关节炎患儿的安全性和疗效，将26名年龄在3至25岁之间的患者随机分配接受吡罗昔康或萘普生治疗。吡罗昔康组疼痛和肿胀关节的数量显著减少（p小于0.05）。研究者的总体评估是，吡罗昔康组67%的患者有临床改善，相比之下，萘普生治疗组为38%。吡罗昔康组的副作用轻微且短暂，没有患者因副作用退出研究。一名萘普生治疗的患者因皮肤皮疹复发而退出研究。尽管由于样本量小，结果应谨慎解读，但在本研究中，吡罗昔康似乎比萘普生更有效且耐受性更好。
